Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 2. 24. (Cancelled)
- 25. (New) The method of claim 1, wherein said activity of a gene product encoded by OC14 is inhibited by administering a compound that inhibits the activity of said gene product.
- 26. (New) The method of claim 25, wherein said compound is selected from the group consisting of a fusion protein, a polypeptide, a peptidomimetic, an antisense polynucleotide, a prodrug, an antibody, a small molecule inhibitor, or a ribozyme.
- 27. (New) The method of claim 25, wherein the activity of said gene product is decreased by at least 1.5-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 28. (New) The method of claim 25, wherein the activity of said gene product is decreased by at least 3-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.

Stashenko, *et al.* U.S.S.N. 10/734,692

- 29. (New) The method of claim 25, wherein the activity of said gene product is decreased by at least 5-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 30. (New) The method of claim 25, wherein the activity of said gene product is decreased by at least 10% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 31. (New) The method of claim 25, wherein the activity of said gene product is decreased by at least 50% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 32. (New) The method of claim 25, wherein the activity of said gene product is decreased by at least 75% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 33. (New) The method of claim 25, wherein the activity of said gene product is decreased by at least 90% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.